NCT05616923View on ClinicalTrials.gov

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Rosacea, Erythematotelangiectatic
Interventions
DRUG

Trametinib

Topical cream containing 0.1 mg/g trametinib

Trial Locations (1)

12208

Samuel S. Stratton VA Medical Center, Albany

Sponsors
All Listed Sponsors
lead

Albany Research Institute, Inc.

OTHER